Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost infusion in trauma patients with hemorrhagic shock-induced endotheliopathy (SHINE)
2019-000936-24Phase 2Completed
- Sponsor
- Capital Region Blood Center
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in endotheliopathy, Physical trauma and hemorrhagic shock comparing Iloprost arm with Placebo arm (2 arms). Primary endpoint: ICU-free days within 28 days. Started Feb 2019; status: completed.
02
Drugs
iloprost
03
Conditions
endotheliopathyPhysical traumahemorrhagic shock
Beyond the preview
Go deeper on 2019-000936-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000936-24.